Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
FDA released a final guidance on in vivo bioequivalence for topical dermatologic corticosteroids, affecting generic drug developers and manufacturers. The guidance provides updated recommendations for demonstrating bioequivalence, potentially altering study requirements for ANDA submissions.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Generic/ANDA manufacturers and branded drug makers developing topical corticosteroids should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately for new studies; existing studies should be evaluated for compliance with final guidance.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA finalized guidance on in vivo bioequivalence methods for topical corticosteroids, replacing draft guidance. It clarifies study design, data analysis, and acceptance criteria.
Who it affects
Generic/ANDA manufacturers and branded drug makers developing topical corticosteroids
What you must do
Review the final guidance and assess impact on ongoing or planned bioequivalence studies for topical corticosteroid products.
Deadline
Immediately for new studies; existing studies should be evaluated for compliance with final guidance.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness